Transport of therapeutic vanadium and ruthenium complexes by blood plasma components

Current Medicinal Chemistry

Volumn 17, Issue 31, 2010, Pages 3701-3738

  Pessoa, J Costa ^a   Tomaz, I ^b  

^a INSTITUTO SUPERIOR TÉCNICO   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

Author keywords

Human serum albumin; Human serum transferrin; Ruthenium; Ruthenium bioavailability; Transport in blood serum; Vanadium; Vanadium bioavailability

Indexed keywords

HISTIDINE; HUMAN SERUM ALBUMIN; INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; KP 1339; KP 418; RUTHENIUM COMPLEX; TRANSFERRIN; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE;

ARTICLE; BINDING AFFINITY; CARBON NUCLEAR MAGNETIC RESONANCE; CIRCULAR DICHROISM; COMPLEX FORMATION; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; DRUG UPTAKE; ELECTRON SPIN RESONANCE; GEL ELECTROPHORESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR STABILITY; MOLECULAR WEIGHT; NONHUMAN; PLASMA;

BIOLOGICAL TRANSPORT; BLOOD PROTEINS; CLINICAL TRIALS AS TOPIC; COORDINATION COMPLEXES; HUMANS; MOLECULAR WEIGHT; PROTEIN BINDING; RUTHENIUM; RUTHENIUM COMPOUNDS; RUTHENIUM RADIOISOTOPES; SERUM ALBUMIN; SPECTRUM ANALYSIS; TRANSFERRIN; VANADIUM; VANADIUM COMPOUNDS;

EID: 78449246414     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793213742     Document Type: Article

References (224)

1. Orvig, C.; Abrams, M.J. Medicinal Inorganic Chemistry: Introduction. Chem. Rev., 1999, 99, 2201-2203.
2. Messori, L.; Marcon, G. In Metal Ions and their Complexes in Medication, Sigel A.; Sigel H., Eds; Dekker: New York, 2004, p 279.
3. Sun, H.; Zhang, L.; Szeto, K.-Y. In Bismuth in Medicine, Dekker: New York, 2004, p 333.
4. Fricker, S.P. Metal based drugs: from serendipity to design. Dalton Trans., 2007, 4903-4917.
5. Hall, M.D.; Dolman, R.C.; Hambley, T.W. In: Metal Complexes in Tumor Diagnosis and as Anticancer Agents, Sigel A.; Sigel H., Eds; Dekker: New York, 2004; pp. 297-322.
6. Natile, G.; Coluccia, M. In Metal Complexes in Tumor Diagnosis and as Anticancer Agents, Sigel A.; Sigel H., Eds; Dekker: New York, 2004; pp. 209-250.
7. Jakupec, M.A.; Galanski, M.; Keppler, B.K. In Metal Complexes in Tumor Diagnosis and as Anticancer Agents, Sigel A.; Sigel H., Eds; Dekker: New York, 2004; pp. 179-208.
8. Barnes, K.R.; Lippard, S.J. In Metal Complexes in Tumor Diagnosis and as Anticancer Agents, Sigel A.; Sigel H., Eds; Dekker: New York, 2004, pp. 143-177.
9. Levina, A.; Mitra, A.; Lay, P.A. Recent developments in ruthenium anticancer drugs. Metallomics, 2009, 1, 458-470.
10. Bruijnincx, P.C.A.; Sadler, P.J. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol., 2008, 12, 197-206.
11. The World Health Organization website, ; 2010.
12. Ang, W.H.; Dyson, P.J. Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy. Eur. J. Inorg. Chem., 2006, 4003-4018.
13. Brabec, V.; Novakova, O. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resist. Update, 2006, 9, 111-122.
14. Dyson, P.J.; Sava, G. Metal-based antitumour drugs in the post genomic era. Dalton Trans., 2006, 1929-1933, and references therein.
15. Hartinger, C.G.; Jakupec, M.A.; Zorbas-Seifried, S.; Groessl, M.; Egger, A.; Berger, W.; Zorbas, H.; Dyson, P.J.; Keppler, B.K. KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients. Chem. Biodivers., 2008, 5, 2140-2155.
16. Jakupec, M.A.; Galanski, M.; Arion, V.B.; Hartinger, C.G.; Keppler, B.K. Antitumour metal compounds: more than theme and variations. Dalton Trans., 2008, 183-194.
17. Timerbaev, A.R.; Hartinger, C.G.; Aleksenko, S.S.; Keppler, B.K. Interactions of antitumor metallodrugs with serum proteins: Advances in characterization using modern analytical methodology. Chem. Rev., 2006, 106, 2224-2248.
18. Clarke, M.J.; Zhu, F.C.; Frasca, D.R. Non-platinum chemotherapeutic metallopharmaceuticals. Chem. Rev., 1999, 99, 2511-2533.
19. Hartinger, C.G.; Dyson, P.J. Bioorganometallic chemistry-from teaching paradigms to medicinal applications. Chem. Soc. Rev., 2009, 38, 391-401.
20. Ronconi, L.; Sadler, P.J. Using coordination chemistry to design new medicines. Coord. Chem. Rev., 2007, 251, 1633-1648.
21. Clarke, M.J. Ruthenium metallopharmaceuticals. Coord. Chem. Rev., 2003, 236, 209-233.
22. Hartinger, C.G.; Zorbas-Seifried, S.; Jakupec, M.A.; Kynast, B.; Zorbas, H.; Keppler, B.K. From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J. Inorg. Biochem., 2006, 100, 891-904.
23. Yan, Y.K.; Melchart, M.; Habtemariam, A.; Sadler, P.J. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes. Chem. Commun., 2005, 4764-4776.
24. Bergamo, A.; Masi, A.; Peacock, A.F.A.; Habtemariam, A.; Sadler, P.J.; Sava, G. In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model. J. Inorg. Biochem., 2010, 104, 79-86.
25. Rehder, D. Bioinorganic Vanadium Chemistry, John Wiley & Sons: New York, 2008.
26. Thompson, K.H.; Chiles, J.; Yuen, V.G.; Tse, J.; McNeill, J.H.; Orvig, C. Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes. J. Inorg. Biochem., 2004, 98, 683-690.
27. Sakurai, H.; Kojima, Y.; Yoshikawa, Y.; Kawabe, K.; Yasui, H. Antidiabetic vanadium(IV) and zinc(II) complexes. Coord. Chem. Rev., 2002, 226, 187-198.
28. Benitez, J.; Guggeri, L.; Tomaz, I.; Costa Pessoa, J.; Moreno Lorenzo, J.; Aviles, F.X.; Garat, B.; Gambino, D. A novel vanadyl complex with a polypyridyl DNA intercalator as ligand: A potential anti-protozoa and anti-tumor agent. J. Inorg. Biochem., 2009, 103, 1386-1394.
29. Benitez, J.; Guggeri, L.; Tomaz, I.; Arrambide, G.; Navarro, M.; Costa Pessoa, J.; Garat, B.; Gambino, D. Design of vanadium mixed-ligand complexes as potential anti-protozoa agents. J. Inorg. Biochem., 2009, 103, 609-616.
30. Ananth, K.M.; Kanthimathi, M.; Nair, B.U. As e.p.r. study of tetradentate Schiff base copper complexes with an N-(CH2)n-N, n=3-6 backbone. Trans. Met. Chem., 2001, 26, 333-338.
31. Maurya, M.R.; Khan, A.A.; Irfan, I.; Azam, A.; Kumar, A.; Costa Pessoa, J. Binuclear Oxidovanadium(IV) and Dioxidovanadium(V) Complexes of 5, 5'-Methylenebis(Dibasic Tridentate) Ligands: Synthesis, Spectral Characterisation, Reactivity, Catalytic and Antiamoebic Activities. Eur. J. Inorg. Chem., 2009, 5377-5390.
32. + cores with binucleating dibasic tetradentate ligands: Synthesis, characterization, catalytic and antiamoebic activities. Dalton Trans., 2010, 39, 1345-1360.
33. Maurya, M.R.; Kumar, A.; Bhat, A.R.; Azam, A.; Bader, C.; Rehder, D. Dioxo- and oxovanadium(V) complexes of thiohydrazone ONS donor ligands: Synthesis, characterization, reactivity, and antiamoebic activity. Inorg. Chem., 2006, 45, 1260-1269.
34. Ghosh, P.; D'Cruz, O.J.; DuMez, D.D.; Peitersen, J.; Uckun, F.M. Structural and functional characterization of seven spermicidal vanadium(IV) complexes: potentiation of activity by methyl substitution on the cyclopentadienyl rings. J. Inorg. Biochem., 1999, 75, 135-143.
35. D'Cruz, O.J.; Waurzyniak, B.; Uckun, F.M. Subchronic (13-week) toxicity studies of intravaginal administration of spermicidal vanadocene acetylacetonato monotriflate in mice. Toxicol., 2002, 170, 31-43.
36. Shigeta, S.; Mori, S.; Yamase, T.; Yamamoto, N.; Yamamoto, N. Anti-RNA virus activity of polyoxometalates. Biomed. Pharmacother., 2006, 60, 211-219.
37. Yasui, H.; Adachi, Y.; Katoh, A.; Sakurai, H. Metallokinetic characteristics of antidiabetic bis(allixinato)oxovanadium(IV)- related complexes in the blood of rat. J. Biol. Inorg. Chem., 2007, 12, 843-853.
38. D'Cruz, O.J.; Dong, Y.H.; Uckun, F.M. Potent dual anti-HIV and spermicidal activities of novel oxovanadium(V) complexes with thiourea non-nucleoside inhibitors of HIV-1 reverse transcriptase. Biochem. Biophys. Res. Commun., 2003, 302, 253-264.
39. Wong, S.Y.; Sun, R.W.Y.; Chung, N.P.Y.; Lin, C.L.; Che, C.M. Physiologically stable vanadium(IV) porphyrins as a new class of anti-HIV agents. Chem. Commun., 2005, 3544-3546.
40. Ross, A.; Soares, D.C.; Covelli, D.; Pannecouque, C.; Budd, L.; Collins, A.; Robertson, N.; Parsons, S.; De Clercq, E.; Kennepohl, P.; Sadler, P.J. Oxovanadium(IV) Cyclam and Bicyclam Complexes: Potential CXCR4 Receptor Antagonists. Inorg. Chem., 2010, 49, 1122-1132.
41. Timerbaev AR, Hartinger CG, Keppler BK. Metallodrug research and analysis using capillary electrophoresis. Trends Anal. Chem., 2006, 25, 868-875.
42. David, S.; Barros, V.; Cruz, C.; Delgado, R. In vitro effect of free and complexed indium(III) against Mycobacterium tuberculosis. FEMS Microbiol. Lett., 2005, 251, 119-124.
43. Maiti, A.; Ghosh, S. Synthesis and reactivity of the oxovanadium(Iv) complexes of 2 N-O donors and potentiation of the antituberculosis activity of one of them on chelation to metalions. J. Inorg. Biochem., 1989, 36, 131-139.
44. Thompson, K.H.; Orvig, C. Vanadium in diabetes: 100 Years from Phase 0 to Phase I. J. Inorg. Biochem., 2006, 100, 1925-1935.
45. Thompson, K.H.; Lichter, J.; LeBel, C.; Scaife, M.C.; McNeil, J.H.; Orvig, C. Vanadium treatment of type 2 diabetes: A view to the future. J. Inorg. Biochem., 2009, 103, 554-558.
46. Evangelou, A.M. Vanadium in cancer treatment. Crit. Rev. Oncol. Hematol., 2002, 42, 249-265.
47. D'Cruz, O.J.; Uckun, F.M. Metvan: a novel oxovanadium(IV) complex with broad spectrum anticancer activity. Expert Opin. Investig. Drugs, 2002, 11, 1829-1836.
48. Papaioannou, A.; Manos, M.; Karkabounas, S.; Liasko, R.; Evangelou, A.M.; Correia, I.; Kalfakakou, V.; Costa Pessoa, J.; Kabanos, T.A. Solid state and solution studies of a vanadium(III)- L-cysteine complex and demonstration of its antimetastatic, antioxidant and inhibition of neutral endopeptidase activity. J. Inorg. Biochem., 2004, 98, 959-968.
49. Noblía, P.; Vieites, M.; Parajón-Costa, B.S.; Baran, E.J.; Cerecetto, H.; Draper, P.; Gonzalez, M.; Piro, O.E.; Castellano, E.E.; Azqueta, A.; Ceráin, A.L.; Monge-Vega, A.; Gambino, D. Vanadium(V) complexes with salicylaldehyde semicarbazone derivatives bearing in vitro anti-tumor activity toward kidney tumor cells (TK-10): crystal structure of [V(V)O2(5-bromosalicylaldehyde semicar-bazone)]. J. Inorg. Biochem., 2005, 99, 443-451.
50. Johnson, T.R.; Mann, B.E.; Teasdale, I.P.; Adams, H.; Foresti, R.; Green, C.J.; Motterlini, R. Metal carbonyls as pharmaceuticals? [Ru(CO)(3)Cl(glycinate)], a CO-releasing molecule with an extensive aqueous solution chemistry. Dalton Trans., 2007, 1500-1508.
51. Clark, J.E.; Naughton, P.; Shurey, S.; Green, C.J.; Johnson, T.R.; Mann, B.E.; Foresti, R.; Motterlini, R. Cardioprotective actions by a water-soluble carbon monoxide-releasing molecule. Circ. Res., 2003, 93, E2-E8.
52. Rajapakse, C.S.K.; Martinez, A.; Naoulou, B.; Jarzecki, A.A.; Suarez, L.; Deregnaucourt, C.; Sinou, V.; Schrevel, J.; Musi, E.; Ambrosini, G.; Schwartz, G.K.; Sanchez-Delgado, R.A. Synthesis, characterization, and in vitro antimalarial and antitumor activity of new ruthenium(II) complexes of chloroquine. Inorg. Chem., 2009, 48, 1122-1131.
53. Bharti, N.; Maurya, M.R.; Naqvi, F.; Azam, A. Synthesis and antiamoebic activity of new cyclooctadiene ruthenium(II) complexes with 2-acetylpyridine and benzimidazole derivatives. Bioorg. Med. Chem. Lett., 2000, 10, 2243-2245.
54. Navarro, M.; Lehmann, T.; Cisneros-Fajardo, E.J.; Fuentes, A.; Sanchez-Delgado, R.A.; Silva, P.; Urbina, J.A. Toward a novel metal-based chemotherapy against tropical diseases. Part 5. Synthesis and characterization of new Ru(II) and Ru(III) clotrimazole and ketoconazole complexes and evaluation of their activity against Trypanosoma cruzi. Polyhedron, 2000, 19, 2319-2325.
55. Sanchez-Delgado, R.A.; Navarro, M.; Lazardi, K.; Atencio, R.; Capparelli, M.; Vargas, F.; Urbina, J.A.; Bouillez, A.; Noels, A.F.; Masi, D. Toward a novel metal based chemotherapy against tropical diseases 4. Synthesis and characterization of new metal-clotrimazole complexes and evaluation of their activity against Trypanosoma cruzi. Inorg. Chim. Acta, 1998, 276, 528-540.
56. Donnici, C.L.; Araujo, M.H.; Oliveira, H.S.; Moreira, D.R.M.; Pereira, V.R.A.; Souza, M.D.; de Castro, M.C.A.B.; Leite, A.C.L. Ruthenium complexes endowed with potent anti-Trypanosoma cruzi activity: Synthesis, biological characterization and structure-activity relationships. Bioorg. Med. Chem., 2009, 17, 5038-5043.
57. Silva, J.J.N.; Pavanelli, W.R.; Gutierrez, F.R.S.; Lima, F.C.A.; da Silva, A.B.F.; Silva, J.S.; Franco, D.W. Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy. J. Med. Chem., 2008, 51, 4104-4114.
58. Pagano, M.; Demoro, B.; Toloza, J.; Boiani, L.; Gonzalez, M.; Cerecetto, H.; Olea-Azar, C.; Norambuena, E.; Gambino, D.; Otero, L. Effect of ruthenium complexation on trypanocidal activity of 5-nitrofuryl containing thiosemicarbazones. Eur. J. Med. Chem., 2009, 44, 4937-4943.
59. Tfouni, E.; Krieger, M.; McGarvey, B.R.; Franco, D.W. Structure, chemical and photochemical reactivity and biological activity of some ruthenium amine nitrosyl complexes. Coord. Chem. Rev., 2003, 236, 57-69.
60. Silva, J.J.J.; Osakabe, A.L.; Pavanelli, W.R.; Silva, J.S.; Franco, D.W. In vitro and in vivo antiproliferative and trypanocidal activities of ruthenium NO donors. Br. J. Pharmacol., 2007, 152, 112-121.
61. Chatterjee, D.; Mitra, A.; De, G.S. Ruthenium Polyaminocar-boxylate Complexes - Prospects for their use as Metallopharma-ceuticals. Platinum Met. Rev., 2006, 50, 2-12.
62. Hutchings, S.R.; Song, D.; Fricker, S.P.; Pang, C.C.Y. The ruthenium-based nitric oxide scavenger, AMD6221, augments cardiovascular responsiveness to noradrenaline in rats with streptozotocin-induced diabetes. Eur. J. Pharmacol, 2005, 528, 132-136.
63. Martinez, A.; Rajapakse, C.S.K.; Jalloh, D.; Dautriche, C.; Sanchez-Delgado, R.A. The antimalarial activity of Ru-chloroquine complexes against resistant Plasmodium falciparum is related to lipophilicity, basicity, and heme aggregation inhibition ability near water/n-octanol interfaces. J. Biol. Inorg. Chem., 2009, 14, 863-871.
64. Martinez, A.; Rajapakse, C.S.K.; Naoulou, B.; Kopkalli, Y.; Davenport, L.; Sanchez-Delgado, R.A. The mechanism of antimalarial action of the ruthenium(II)-chloroquine complex [RuCl2(CQ)](2). J. Biol. Inorg. Chem., 2008, 13, 703-712.
65. Blackie, M.A.L.; Beagley, P.; Croft, S.L.; Kendrick, H.; Moss, J.R.; Chibale, K. Metallocene-based antimalarials: An exploration into the influence of the ferrocenyl moiety on in vitro antimalarial activity in chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum. Bioorg. Med. Chem., 2007, 15, 6510-6516.
66. Gabbiani, C.; Messori, L.; Cinellu, M.A.; Casini, A.; Mura, P.; Sannella, A.R.; Severini, C.; Majori, G.; Bilia, A.R.; Vincieri, F.F. Outstanding plasmodicidal properties within a small panel of metallic compounds: Hints for the development of new metal-based antimalarials. J. Inorg. Biochem., 2009, 103, 310-312.
67. Rehder, D. The bioinorganic chemistry of vanadium. Angew. Chem. Int. Ed., 1991, 30, 148-167.
68. Bertini, I.; Canti, G.; Luchinat, C. Preparation and Characterization of the Vanadium-(III) Derivative of transferrin. Inorg. Chim. Acta-Bioinorg. Chem., 1982, 67, L21-L23.
69. Vilas Boas, L.F.; Costa Pessoa, J. In Comprehensive Coordination Chemistry, G.Wilkinson; R.D.Gillard; J.A.McCleverty, Eds; Pergamon Press: Oxford, 1987, Vol 3, pp. 453-583.
70. Reisner, E.; Arion, V.B.; Keppler, B.K.; Pombeiro, A.J.L. Electron-transfer activated metal-based anticancer drugs. Inorg. Chim. Acta, 2008, 361, 1569-1583.
71. Brindell, M.; Stawoska, I.; Supel, J.; Skoczowski, A.; Stochel, G.; van Eldik, R. The reduction of (ImH)[trans-(RuCl4)-Cl-III(dmso)(Im)] under physiological conditions: preferential reaction of the reduced complex with human serum albumin. J. Biol. Inorg. Chem., 2008, 13, 909-918.
72. Cetinbas, N.; Webb, M.I.; Dubland, J.A.; Walsby, C.J. Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR. J. Biol. Inorg. Chem., 2010, 15, 131-145.
73. Hu, W.B.; Luo, Q.; Ma, X.Y.; Wu, K.; Liu, J.A.; Chen, Y.; Xiong, S.X.; Wang, J.P.; Sadler, P.J.; Wang, F.Y. Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes. Chem. Eur. J., 2009, 15, 6586-6594.
74. Gorzsás, A.; Andersson, I.; Pettersson, L. On the fate of vanadate in human blood. Eur. J. Inorg. Chem., 2006, 3559-3565.
75. - by ascorbic acid and glutathione: kinetic studies of pro-drugs for the enhancement of insulin action. Inorg. Chem., 2002, 41, 1357-1364.
76. Arrigoni, O.; De Tullio, M.C. Ascorbic acid: much more than just an antioxidant. Biochim. Biophys. Acta, Gen. Subj., 2002, 1569, 1-9.
77. Quian, Z.M.; Li, H.; Ho, K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev., 2002, 54, 561-587.
78. Gomme, P.T; McCann, K.B. Transferrin: structure, function and potential therapeutic actions. Drug Discov. Today, 2005, 10(4), 267-273.
79. Sun, H.Z.; Cox, M.C.; Li, H.Y.; Sadler, P.J. Rationalisation of metal binding to transferrin: Prediction of metal-protein stability constants. In Metal Sites in Proteins and Models. Iron Centres, Hill, H.A.O.; Sadler, P.J.; Thomsom, A.J. Eds.; Springer: Berlin, 1999; pp. 71-102.
80. Li, H.Y.; Qian, Z.M. Transferrin/transferrin receptor-mediated drug delivery. Med. Res. Rev., 2002, 22, 225-250.
81. Sun, H.Z.; Li, H.Y.; Sadler, P.J. Transferrin as a metal ion mediator. Chem. Rev., 1999, 99, 2817-2842.
82. MacGillivray, R.T.A.; Bewley, M.C.; Smith, C.A.; He, Q.Y.; Mason, A.B.; Woodworth, R.C.; Baker, E.N. Mutation of the iron ligand his 249 to Glu in the N-lobe of human transferrin abolishes the dilysine trigger but does not significantly affect iron release. Biochemistry, 2000, 39, 1211-1216.
83. Byrne, S.L.; Mason, A.B. Human serum transferrin: a tale of two lobes. Urea gel and steady state fluorescence analysis of recombinant transferrins as a function of pH, time, and the soluble portion of the transferrin receptor. J. Biol. Inorg. Chem., 2009, 14, 771-781.
84. Li, H.Y.; Sun, H.Z.; Qian, Z.M. The role of the transferrin-transferrin-receptor system in drug delivery and targeting. Trends Pharmacol. Sci., 2002, 23, 206-209.
85. Kratz, F. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J. Control Rel., 2008, 132, 171-183.
86. Colmenarejo, G. In silico prediction of drug-binding strengths to human serum albumin. Med. Res. Rev., 2003, 23, 275-301.
87. Ang, W.H.; Daldini, E.; Juillerat-Jeanneret, L.; Dyson, P.J. Strategy to tether organometallic ruthenium-arene anticancer compounds to recombinant human serum albumin. Inorg. Chem., 2007, 46, 9048-9050.
88. Mura, P.; Camalli, M.; Casini, A.; Gabbiani, C.; Messori, L. Trans-cis-cis-[RuCl2(DMSO)(2)(2-amino-5-methyl-thiazole)(2)], (PMRu52), a novel ruthenium(II) compound acting as a strong inhibitor of cathepsin B. J. Inorg. Biochem., 2010, 104, 111-117.
89. Ravera, M.; Baracco, S.; Cassino, C.; Colangelo, D.; Bagni, G.; Sava, G.; Osella, D. Electrochemical measurements confirm the preferential bonding of the antimetastatic complex [ImH][RuCl4(DSMO)(Im)] (NAMI-A) with the proteins and the weak interaction with nucleobases. J. Inorg. Biochem., 2004, 98, 984-990.
90. Steinhardt, J.; Krijn, J.; Leidy, J.G. Differences between bovine and human serum albumins: Binding isotherms, optical rotatory dispersion, viscosity, hydrogen ion titration, and fluorescence effects. Biochemistry, 1971, 10, 4005-4015.
91. Nagaoka, M.H.; Yamazaki, T.; Maitani, T. Binding patterns of vanadium ions with different valence states to human serum transferrin studied by HPLC/high-resolution ICP-MS. Biochem. Biophys. Res. Commun., 2002, 296, 1207-1214.
92. Zhang, S.Q.; Zhong, X.Y.; Chen, G.H.; Lu, W.L.; Zhang, Q. The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats. J. Pharm. Pharmacol., 2008, 60, 99-105.
93. Kiss, T.; Jakusch, T.; Bouhsina, S.; Sakurai, H.; Enyedy, E. Binding constant of VO to transferrin. Eur. J. Inorg. Chem., 2006, 3607-3614.
94. Jakusch, T.; Hollender, D.; Enyedy, E.A.; Gonzalez, C.S.; Montes-Bayon, M.; Sanz-Medel, A.; Costa Pessoa, J.; Tomaz, I.; Kiss, T. Biospeciation of various antidiabetic VO(IV) compounds in serum. Dalton Trans., 2009, 2428-2437.
95. Groessl, M.; Hartinger, C.G.; Polec-Pawlak, K.; Jarosz, M.; Keppler, B.K. CE hyphenated to ICP-MS: A novel approach for the analysis of anticancer metallodrug KP1019 in human serum and plasma. Electrophoresis, 2008, 29, 2224-2232.
96. Som, P.; Oster, Z.H.; Matsui, K.; Guglielmi, G.; Persson, B.R.R.; Pellettieri, M.L.; Srivastava, S.C.; Richards, P.; Atkins, H.L.; Brill, A.B. Ru-97-transferrin uptake in tumor and abscess. Eur. J. Nucl. Med., 1983, 8, 491-494.
97. Groessl, M.; Reisner, E.; Hartinger, C.G.; Eichinger, R.; Semenova, O.; Timerbaev, A.R.; Jakupec, M.A.; Arion, V.B.; Keppler, B.K. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl- 1,2,4-triazole): Aquation, redox properties, protein binding, and antiproliferative activity. J. Med. Chem., 2007, 50, 2185-2193.
98. Kratz, F.; Keppler, B.K.; Hartmann, M.; Messori, L.; Berger, M.R. Comparison of the antiproliferative activity of two antitumour ruthenium(III) complexes with their apotransferrin and transferrin-bound forms in a human colon cancer cell line. Met. Based Drugs, 1996, 3, 15-23.
99. Liu, M.M.; Lim, Z.J.; Gwee, Y.Y.; Levina, A.; Lay, P.A. Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity. Angew. Chem. Int. Ed., 2010, 49, 1661-1664.
100. Smith, C.A.; Ainscough, E.W.; Brodie, A.M. Complexes of Human Lactoferrin with Vanadium in Oxidation States +3, +4 and +5. J. Chem. Soc., Dalton Trans, 1995, 1121-1126.
101. Du, H.; Xiang, J.; Zhang, Y.; Tang, Y.; Xu, H. Binding of V(IV) to human transferrin: potential relevance to anticancer activity of vanadocene dichloride. J. Inorg. Biochem., 2008, 102, 146-149.
102. Chasteen, N.D.; Grady, J.K.; Holloway, C.E. Characterization of binding, kinetics, and redox stability of vanadium(IV) and vanadium(V) protein complexes in serum. Inorg. Chem., 1986, 25, 2754-2760.
103. Jakusch, T.; Dean, A.; Oncsik, T.; Benyei, A.C.; Di Marco, V.; Kiss, T. Vanadate complexes in serum: a speciation modeling study. Dalton Trans., 2010, 39, 212-220.
104. Harris, W.R. Thermodynamics of anion binding to human-serum transferrin. Biochemistry, 1985, 24, 7412-7418.
105. Harris, W.R.; Carrano, C.J. Binding of Vanadate to Human-Serum Transferrin. J. Inorg. Biochem., 1984, 22, 201-218.
106. Liboiron, B.D.; Thompson, K.H.; Hanson, G.R.; Lam, E.; Aebischer, N.; Orvig, C. New insights into the interactions of serum proteins with Bis(maltolato)oxovanadium(IV): Transport and biotransformation of insulin-enhancing vanadium pharmaceuticals. J. Am. Chem. Soc., 2005, 127, 5104-5115.
107. Mustafi, D.; Galtseva, E.V.; Krzystek, J.; Brunel, L.C.; Makinen, M.W. High-frequency EPR studies of VO2+ in low-temperature glasses. J. Phys. Chem. A, 1999, 103, 11279-11286.
108. Chasteen, N.D. Human serotransferrin: structure and Function. Coord. Chem. Rev., 1977, 22, 1-36.
109. Sanna, D.; Micera, G.; Garribba, E. On the Transport of Vanadium in Blood Serum. Inorg. Chem., 2009, 48, 5747-5757.
110. 2+ ion with human serum transferrin and albumin. J. Inorg. Biochem., 2009, 103, 648-655.
111. Kiss, T.; Jakusch, T.; Hollender, D.; Dornyei, D.; Enyedy, E.A.; Costa Pessoa, J.; Sakurai, H.; Sanz-Medel, A. Biospeciation of antidiabetic VO(IV) complexes. Coord. Chem. Rev., 2008, 252, 1153-1162.
112. 2+ compounds. J. Biol. Inorg. Chem., DOI 10.1007/s00775-010-0647-9.
113. Sanna, D.; Micera, G.; Garribba, E. New Developments in the Comprehension of the Biotransformation and Transport of Insulin-Enhancing Vanadium Compounds in the Blood Serum. Inorg. Chem., 2010, 49, 174-187.
114. Yasui, H.; Takechi, K.; Sakurai, H. Metallokinetic analysis of disposition of vanadyl complexes as insulin-mimetics in rats using BCM-ESR method. J. Inorg. Biochem., 2000, 78, 185-196.
115. Takino, T.; Yasui, H.; Yoshitake, A.; Hamajima, Y.; Matsushita, R.; Takada, J.; Sakurai, H. A new halogenated antidiabetic vanadyl complex bis(5-iodopicalinato)oxovanadium(IV): in vitro and in vivo insulinomimetic evaluations and metallokinetic analysis. J. Biol. Inorg. Chem., 2001, 6, 133-142.
116. Messori, L.; Gonzales Vilchez, F.; Vilaplana, R.; Piccioli, F.; Alessio, E.; Keppler, B.K. Binding of antitumor ruthenium(III) complexes to plasma proteins. Met. Based Drugs, 2000, 7, 335-342.
117. Kratz, F.; Hatrmann, M.; Keppler, B.K.; Messori, L. The binding properties of two antitumor Ruthenium(III) complexes to apotransferrin. J. Biol. Chem., 1994, 269, 2581-2588.
118. Butler, A.; Eckert, H. 51V NMR as a Probe of vanadium(V) coordination to Human Apotransferrin. J. Am. Chem. Soc., 1989, 111, 2802-2809.
119. Saponja, J.A.; Vogel, H.J. Metal-ion binding properties of the transferrins: A vanadium-51 NMR study. J. Inorg. Biochem., 1996, 62, 253-270.
120. Yasui, H.; Kunori, Y.; Sakurai, H. Specific binding of vanadyl ion with thiolate of the cysteine-34 residue in serum albumin, demonstrated by CD Spectroscopy and kinetic property. Chem. Lett., 2003, 32, 1032-1033.
121. Trynda-Lemiesz, L.; Kozlowski, H.; Katsaros, N. Interaction of cis- and trans-RuCl(DMSO)4 with human serum albumin. Met. Based Drugs, 2000, 7, 293-299.
122. Trynda-Lemiesz, L.; Keppler, B.K.; Kozlowski, H. Studies on the interactions between human serum albumin and imidazolium [trans-tetrachlorobis (imidazol) ruthenate(III)]. J. Inorg. Biochem., 1999, 73, 123-128.
123. Trynda-Lemiesz, L.; Karaczyn, A.; Keppler, B.K.; Kozlowski, H. Studies on the interactions between human serum albumin and trans-indazolium (bisindazole) tetrachlororuthenate(III). J. Inorg. Biochem., 2000, 78, 341-346.
124. Messori, L.; Orioli, P.; Vullo, D.; Alessio, E.; Lengo, E. A spectroscopic study of the reaction of NAMI, a novel ruthenium(III) anti-neoplastic complex, with bovine serum albumin. Eur. J. Biochem., 2000, 267, 1206-1213.
125. Pieper, T.; Keppler, B. K. Tumor-inhibiting ruthenium complexes - formulation and analytical characterization. Analysis, 1998, 26, M84-M87.
126. Kratz, F.; Keppler, B.K.; Messori, L.; Smith, C.; Baker, E.N. Protein binding properties of antitumour Ru(III) complexes to human apoTransferrin and apoLactoferrin. Met. Based Drugs, 1994, 169-173.
127. Bergamo, A.; Messori, L.; Piccioli, F.; Cocchietto, M.; Sava, G. Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin. Invest. New Drugs, 2003, 21, 401-411.
128. Dolman, R.C.; Deacon, G.B.; Hambley, T.W. Studies of the binding of a series of platinum(IV) complexes to plasma proteins. J. Inorg. Biochem., 2002, 88, 260-267.
129. Einhauser, T.J.; Galanski, M.; Keppler, B.K. Determination of platinum in protein-bound COOP and DBP by inductively coupled plasma optical emission spectrometry and electrothermal atomic absorption spectrometry. J. Anal. At. Spectrom., 1996, 11, 747-750.
130. Trynda-Lemiesz, L.; Kozlowski, H.; Keppler, B.K. Effect of cis-, trans-diamminedichloroplatinum(II) and DBP on human serum albumin. J. Inorg. Biochem., 1999, 77, 141-146.
131. Bordbar, A.K.; Creagh, A.L.; Mohammadi, F.; Haynes, C.A.; Orvig, C. Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin. J. Inorg. Biochem., 2009, 103, 643-647.
132. Nagaoka, M.H.; Akiyama, H.; Maitani, T. Binding patterns of vanadium to transferrin in healthy human serum studied with HPLC/high resolution ICP-MS. Analyst, 2004, 129, 51-54.
133. De Cremer, K.; Cornelis, R.; Strijckmans, K.; Dams, R.; Lameire, N.; Vanholder, R. Behaviour of vanadate and vanadium-transferrin complex on different anion-exchange columns. Application to in vivo V-48-labelled rat serum. J. Chromatogr. B, 2002, 775, 143-152.
134. Fernandes, K.G.; Montes-Bayon, M.; Gonzalez, E.B.; Del Castillo-Busto, E.; Nobrega, J.A.; Sanz-Medel, A. Complementary FPLC-ICP-MS and MALDI-TOF for studying vanadium association to human serum proteins. J. Anal. At. Spectrom., 2005, 20, 210-215.
135. Casini, A.; Gabbiani, C.; Mastrobuoni, G.; Messori, L.; Moneti, G.; Pieraccini, G. Exploring metallodrug-protein interactions by ESI mass spectrometry: The reaction of anticancer platinum drugs with horse heart cytochrome c. ChemMedChem, 2006, 1, 413-417.
136. Foteeva, L.S.; Timerbaev, A.R. Application of capillary electrophoresis to the analysis of metal-containing pharmaceuticals. J. Anal. Chem., 2009, 64, 1206-1213.
137. Hartinger, C.G.; Schluga, P.; Galanski, M.; Baumgartner, C.; Timerbaev, A.R.; Keppler, B.K. Tumor-inhibiting platinum(II) complexes with aminoalcohol ligands: Comparison of the mode of action by capillary electrophoresis and electrospray ionization-mass spectrometry. Electrophoresis, 2003, 24, 2038-2044.
138. Hartinger, C.G.; Keppler, B.K. CE in anticancer metallodrug research - an update. Electrophoresis, 2007, 28, 3436-3446.
139. Timerbaev, A.R.; Rudnev, A.V.; Semenova, O.; Hartinger, C.G.; Keppler, B.K. Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis. Anal. Biochem., 2005, 341, 326-333.
140. Shmykov, A.Y.; Filippov, V.N.; Foteeva, L.S.; Keppler, B.K.; Timerbaev, A.R. Toward high-throughput monitoring of metallodrug-protein interaction using capillary electrophoresis in chemically modified capillaries. Anal. Biochem., 2008, 379, 216-218.
141. Polec-Pawlak, K., Abramski, J. K., Semenova, O., Hartinger, C. G., Timerbaev, A. R., Keppler, B. K., and Jarosz, M. Platinum group metallodrug-protein binding studies by CE - ICP-MS: A further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins. Electrophoresis, 2006, 27, 1128-1135.
142. Ascone, I.; Messori, L.; Casini, A.; Gabbiani, C.; Balerna, A.; Dell'Unto, F.; Castellano, A.C. Exploiting soft and hard X-ray absorption spectroscopy to characterize metallodrug/protein interactions: The binding of [trans-RuCl4(Im)(dimethylsulfoxide)] [ImH] (Im = imidazole) to bovine serum albumin. Inorg. Chem., 2008, 47, 8629-8634.
143. Yang, L.; Sturgeon, R.E.; Prince, D.; Gabos, S. Determination of vanadium in biological fluids using HR-ICP-MS. J. Anal. At. Spectrom., 2002, 17, 1300-1303.
144. Fukui, K.; Ohyanishiguchi, H.; Nakai, M.; Sakurai, H.; Kamada, H. Detection of Vanadyl-Nitrogen Interaction in Organs of the Vanadyl-Treated Rat - Electron-Spin Echo Envelope Modulation Study. FEBS Lett., 1995, 368, 31-35.
145. Thompson, K.H.; Liboiron, B.D.; Sun, Y.; Bellman, K.D.D.; Setyawati, I.A.; Patrick, B.O.; Karunaratne, V.; Rawji, G.; Wheeler, J.; Sutton, K.; Bhanot, S.; Cassidy, C.; McNeil, J.H.; Yuen, V.G.; Orvig C. Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential. J. Biol. Inorg. Chem., 2003, 8, 66-74.
146. Rehder, D.; Costa Pessoa, J.; Geraldes, C.F.G.C.; Castro, M.M.C.A.; Kabanos T.A.; Kiss T.; Meier, B.; Micera, G.; Pettersson, L.; Rangel, M.; Salifoglou, A.; Turel, I.; Wang, D. In vitro study of the insulin mimetic behaviour of vanadium (IV, V) coordination compounds. J. Biol. Inorg. Chem., 2002, 7, 384-396.
147. Heinz, A.; Rubinson, K.A.; Grantham, J.J. The transport and accumulation of oxovanadium compounds in human erythrocytes in vitro. J. Lab. Clin. Med., 1982, 100, 593-611.
148. Cantley, L.C.; Resh, M.D.; Guidotti, G. Vanadate inhibits red-cell (Na+, K+)atpase from cytoplasmic side. Nature, 1978, 272, 552-554.
149. Macara, I.G.; Kustin, K.; Cantley, L.C. Glutathione Reduces Cytoplasmic Vanadate Mechanism and Physiological Implications. Biochim. Biophys. Acta, 1980, 629, 95-106.
150. Harris, W.R.; Friedman, S.B.; Silberman, D. Behavior of vanadate an vanadyl ion in canine blood. J. Inorg. Biochem., 1984, 20, 157-169.
151. 13C]Glucose and 1 H NMR Analysis of the Lacate Methyl Signal. Magn. Res. Med., 2004, 51, 1283-1286.
152. Cantley, L.C.; Aisen, P. Fate of cytoplasmic vanadium - implications on (Na,K)-atpase inhibition. J. Biol. Chem., 1979, 254, 1781-1784.
153. De Cremer, K.; Van Hulle, M.; Chery, C.; Cornelis, R.; Strijckmans, K.; Dams, R.; Lameire, N.; Vanholder, R. Fractionation of vanadium complexes in serum, packed cells and tissues of Wistar rats by means of gel filtration and anion-exchange chromatography. J. Biol. Inorg. Chem., 2002, 7, 884-890.
154. Dornyei, A.; Marcão, S.; Costa Pessoa, J.; Jakusch, T.; Kiss, T. Interactions of insulin-mimetic vanadium complexes with the cell constituents ATP and glutathione. Eur. J. Inorg. Chem., 2006, 3614-3621.
155. Nielsen, F.H. In Metal ions in biological systems, Sigel A.; Sigel H., Eds; Marcel Dekker: New York, 1995, pp. 543-573.
156. Sabbioni, E.; Marafante, E.; Amantini, L.; Ubertalli, L.; Birattari, C. Similarity in metabolic patterns of different chemical species of vanadium in rat. Bioinorg. Chem., 1978, 8, 503-515.
157. Sakurai, H.; Shimomura, S.; Fukuzawa, K.; Ishizu, K. Detection of oxovanadium(Iv) and characterization of its ligand environment in subcellular-fractions of the liver of rats treated with pentavalent vanadium(V). Biochem. Biophys. Res. Commun., 1980, 96, 293-298.
158. Yasui, H.; Tamura,; Takino, T.; Sakurai, H. Structure-dependent metallokinetics of antidiabetic vanadyl-picolinate complexes in rats: studies on solution structure, insulinomimetic activity, and metallokinetics, J. Inorg. Biochem., 2002, 91, 327-338.
159. Willsky, G.R.; Goldfine, A.B.; Kostyniak, P.J.; McNeill, J.H.; Yang, L.Q.; Khan, H.R.; Crans, D.C. Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV). J. Inorg. Biochem., 2001, 85, 33-42.
160. Rajendiran, V.; Karthik, R.; Palaniandavar, M.; Stoeckli-Evans, H.; Periasamy, V.S.; Akbarsha, M.A.; Srinag, B.S.; Krishnamurthy, H. Mixed-ligand Cu(II)-phenolate complexes. DNA Effect of Coligand on Enhanced DNA and Protein Binding, DNA Cleavage, and Anticancer Activity. Inorg. Chem., 2007, 46, 8208-8221.
161. Chery, C.C.; De Cremer, K.; Dumont, E.; Cornelis, R.; Moens, L. Vanadium speciation in serum by means of blue native gel electrophoresis. Electrophoresis, 2002, 23, 3284-3288.
162. White, L.K.; Chasteen, N.D. Q-Band electron-paramagnetic resonance study of vanadyl(Iv)-labeled human serotransferrin. J. Phys. Chem., 1979, 83, 279-284.
163. Hanna, P.M.; Chasteen, N.D.; Rottman, G.A.; Aisen, P. Iron-binding to horse spleen apoferritin - a vanadyl endor spin probe study. Biochemistry, 1991, 30, 9210-9216.
164. Eaton, S.S.; Dubach, J.; More, K.M.; Eaton, G.R.; Thurman, G.; Ambruso, D.R. Comparison of the electron-spin echo envelope modulation (eseem) for human lactoferrin and transferrin complexes of copper(Ii) and vanadyl ion. J. Biol. Chem., 1989, 264, 4776-4781.
165. Saponja, J.A.; Vogel, H.J. Metal-ion binding properties of the transferrins: a V NMR study. J. Inorg. Biochem., 1996, 62, 253-270.
166. Chasteen, N.D.; Lord, E.M.; Thompson, H.J.; Grady, J.K. Vanadium complexes of transferrin and ferritin in the rat. Biochim. Biophys. Acta, 1986, 884, 84-92.
167. Crans, D.C.; Bunch, R.L.; Theisen, L.A. Interaction of trace levels of vanadium(Iv) and vanadium(V) in biological-systems. J. Am. Chem. Soc., 1989, 111, 7597-7607.
168. Purcell, M.; Neault, J.F.; Malonga, H.; Arakawa, H.; Tajmir-Riahi, H.A. Interaction of human serum albumin with oxovanadium ions studied by FT-IR spectroscopy and gel and capillary electrophoresis. Can. J. Chem., 2001, 79, 1415-1421.
169. Chasteen, N.D.; Francavilla, J. Electron-paramagnetic resonance study of vanadyl(Iv) - serum-albumin complexes. J. Phys. Chem., 1976, 80, 867-871.
170. Nechay, B.R.; Nanninga, L.B.; Nechay, P.S.E. Vanadyl (IV) and vanadate (V) binding to selected endogenous phosphate, carboxyl, and amino ligands - calculations of cellular vanadium species distribution. Arch. Biochem. Biophys., 1986, 251, 128-138.
171. Jiang, F.S.; Makinen, M.W. NMR and ENDOR confornational studies of the vanadyl guanosine 5'-monophosphate comples in hydrogen-bonded quartet assemblies. Inorg. Chem., 1995, 34, 1736-1744.
172. Kiss, T.; Kiss, E.; Garribba, E.; Sakurai, H. Speciation of insulin-mimetic VO(IV)-containing drugs in blood serum. J. Inorg. Biochem., 2000, 80, 65-73.
173. Zekany, L.; Nagypal, I. In Computational Methods for the Determination of Stability Constants, D. Leggett, Ed; Plenum: New York, 1985, pp. 291-353.
174. Gatjens, J.; Meier, B.; Kiss, T.; Nagy, E.M.; Buglyo, P.; Sakurai, H.; Kawabe, K.; Rehder, D. A new family of insulin-mimetic vanadium complexes derived from 5-carboalkoxypicolinates. Chem. Eur. J., 2003, 9, 4924-4935.
175. Setyawati, I.A.; Thompson, K.H.; Yuen, V.G.; Sun, Y.; Battell, M.; Lyster, D.M.; Vo, C.; Ruth, T.J.; Zeisler, S.; McNeill, J.H.; Orvig, C. Kinetic analysis and comparison of uptake, distribution, and excretion of V-48-labeled compounds in rats. J. Appl. Physiol., 1998, 84, 569-575.
176. Tang, S.; Lu, B.; Fantus, I.G. Stimulation of I-125-transferrin binding and Fe-59 uptake in rat adipocytes by vanadate: Treatment time determines apparent tissue sensitivity. Metab. Clin. Exp., 1998, 47, 630-636.
177. Kostova, I. Ruthenium complexes as anticancer agents. Curr. Med. Chem., 2006, 13, 1085-1107.
178. Groessl, M.; Hartinger, C.G.; Polec-Pawlak, K.; Jarosz, M.; Dyson, P.J.; Keppler, B.K. Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Chem. Biodivers., 2008, 5, 1609-1614.
179. Bergamo, A.; Sava, G. Ruthenium complexes can target determinants of tumour malignancy. Dalton Trans., 2007, 1267-1272.
180. Rademaker-Lakhai, J.M.; van den Bongard, D.; Pluim, D.; Beijnen, J.H.; Schellens, J.H.M. A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin. Cancer Res., 2004, 10, 3717-3727.
181. Scolaro, C.; Bergamo, A.; Brescacin, L.; Delfino, R.; Cocchietto, M.; Laurenczy, G.; Geldbach, T.J.; Sava, G.; Dyson, P.J. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes. J. Med. Chem., 2005, 48, 4161-4171.
182. Casini, A.; Gabbiani, C.; Sorrentino, F.; Rigobello, M.P.; Bindoli, A.; Geldbach, T.J.; Marrone, A.; Re, N.; Hartinger, C.G.; Dyson, P.J.; Messori, L. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium (II)-arene compounds. J. Med. Chem., 2008, 51, 6773-6781.
183. Ang, W.H.; Daldini, E.; Scolaro, C.; Scopelliti, R.; Juillerat-Jeannerat, L.; Dyson, P.J. Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis. Inorg. Chem., 2006, 45, 9006-9013.
184. Scolaro, C.; Chaplin, A.B.; Hartinger, C.G.; Bergamo, A.; Cocchietto, M.; Keppler, B.K.; Sava, G.; Dyson, P.J. Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy. Dalton Trans., 2007, 5065-5072.
185. Renfrew, A.K.; Phillips, A.D.; Egger, A.E.; Hartinger, C.G.; Bosquain, S.S.; Nazarov, A.A.; Keppler, B.K.; Gonsalvi, L.; Peruzzini, M.; Dyson, P.J. Influence of structural variation on the anticancer activity of RAPTA-Type complexes: ptn versus pta. Organometallics, 2009, 28, 1165-1172.
186. Mura, P.; Camalli, M.; Messori, L.; Piccioli, F.; Zanello, P.; Corsini, M. Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the Ruthenium(III) complexes [TzH][trans-RUCl4(Tz)(2)] and [TzH][trans-RUCl4(DMSO)(Tz)]center dot(DMSO), the thiazole analogues of antitumor ICR and NAMI-A. Inorg. Chem., 2004, 43, 3863-3870.
187. Berger, I.; Hanif, M.; Nazarov, A.A.; Hartinger, C.G.; John, R.O.; Kuznetsov, M.L.; Groessl, M.; Schmitt, F.; Zava, O.; Biba, F.; Arion, V.B.; Galanski, M.; Jakupec, M.A.; Juillerat-Jeannerat, L.; Dyson, P.J.; Keppler, B.K. In vitro anticancer activity and biologically relevant metabolization of organometallic ruthenium complexes with carbohydrate-based ligands. Chem. Eur. J., 2008, 14, 9046-9057.
188. Scolaro, C.; Hartinger, C.G.; Allardyce, C.S.; Keppler, B.K.; Dyson, P.J. Hydrolysis study of the bifunctional antitumour compound RAPTA-C, [Ru(eta(6)-p-cymene)Cl-2(pta). J. Inorg. Biochem., 2008, 102, 1743-1748.
189. Smith, C.A.; SutherlandSmith, A.J.; Keppler, B.K.; Kratz, F.; Baker, E.N. Binding of ruthenium(III) anti-tumor drugs to human lactoferrin probed by high resolution X-ray crystallographic structure analyses. J. Biol. Inorg. Chem., 1996, 1, 424-431.
190. Besker, N.; Coletti, C.; Marrone, A.; Re, N. Aquation of the ruthenium-based anticancer drug NAMI-A: A density functional study. J. Phys. Chem. B, 2008, 112, 3871-3875.
191. Kung, A.; Pieper, T.; Wissiack, R.; Rosenberg, E.; Keppler, B.K. Hydrolysis of the tumor-inhibiting ruthenium[lll) complexes Hlm trans-[RnCl4(im)(2)] and Hlnd trans[RuCl4(ind)(2)] investigated by means of HPCE and HPLC-MS. J. Biol. Inorg. Chem., 2001, 6, 292-299.
192. Schluga, P.; Hartinger, C.G.; Egger, A.; Reisner, E.; Galanski, M.; Jakupec, M.A.; Keppler, B.K. Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP. Dalton Trans., 2006, 1796-1802.
193. Sulyok, M.; Hann, S.; Hartinger, C.G.; Keppler, B.K.; Stingeder, G.; Koellensperger, G. Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(III) compound with plasma proteins. J. Anal. At. Spectrom., 2005, 20, 856-863.
194. Casini, A.; Guerri, A.; Gabbiani, C.; Messori, L. Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: New insights from X-ray diffraction and mass spectrometry studies. J. Inorg. Biochem., 2008, 995-1006.
195. Will, J.; Kyas, A.; Sheldrick, W.S.; Wolters, D. Identification of (eta(6)-arene) ruthenium(II) protein binding sites in E-coli cells by combined multidimensional liquid chromatography and ESI tandem mass spectrometry: specific binding of [(eta(6)-p-cymene)RuCl2(DMSO)] to stress-regulated proteins and to helicases. J. Biol. Inorg. Chem., 2007, 12, 883-894.
196. Wang, F.Y.; Bella, J.; Parkinson, J.A.; Sadler, P.J. Competitive reactions of a ruthenium arene anticancer complex with histidine, cytochrome c and an oligonucleotide. J. Biol. Inorg. Chem., 2005, 10, 147-155, and references therein.
197. Winkler, J.R.; Gray, H.B. Electron-Transfer in ruthenium-modified proteins. Chem. Rev., 1992, 92, 369-379.
198. Luo, J.; Wishart, J.F.; Isied, S.S. Site-dependent stereoselective binding of ruthenium aquobipyridine complexes to histidine side chains in horse heart. J. Am. Chem. Soc., 1998, 120, 12970-12971.
199. Mcnae, I.W.; Fishburne, K.; Habtemariam, A.; Hunter, T.M.; Melchart, M.; Wang, F.Y.; Walkinshaw, M.D.; Sadler, P.J. Half-sandwich arene ruthenium(II)-enzyme complex. Chem. Commun., 2004, 1786-1787.
200. Grotjahn, D.B. Arene-selective peptide and protein derivatization. Coord. Chem. Rev., 1999, 192, 1125-1141.
201. Esposito, B.P.; Najjar, R. Interactions of antitumoral platinum-group metallodrugs with albumin. Coord. Chem. Rev., 2002, 232, 137-149.
202. Trynda-Lemiesz, L.; Luczkowski, M. Impact of potential blockers on Ru(III) complex binding to human serum albumin. Bioinorg. Chem. Apllications, 2003, 1, 141-150.
203. Mura, P.; Camalli, M.; Messori, L.; Piccioli, F.; Zanello, P.; Corsini, M. Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the Ruthenium(III) complexes [TzH][trans-RUCl4(Tz)(2)] and [TzH][trans-RUCl4(DMSO)(Tz)]center dot(DMSO), the thiazole analogues of antitumor ICR and NAMI-A. Inorg. Chem., 2004, 43, 3863-3870.
204. Mura, P.; Camalli, M.; Bindoli, A.; Sorrentino, F.; Casini, A.; Gabbiani, C.; Corsini, M.; Zanello, P.; Rigobello, M.P.; Messori, L. Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis(2-amino-5methylthiazole)tetrachlororuthenate(III)]: First report of relevant thioredoxin reductase inhibition for a ruthenium compound. J. Med. Chem., 2007, 50, 5871-5874.
205. Mura, P.; Piccioli, F.; Gabbiani, C.; Camalli, M.; Messori, L. Structure-function relationships within keppler-type antitumor ruthenium(III) complexes: the case of 2-aminothiazolium[trans-tetrachlorobis(2-aminothiazole)ruthenate(III)]. Inorg. Chem., 2005, 44, 4897-4899.
206. Khalaila, I.; Bergamo, A.; Bussy, F.; Sava, G.; Dyson, P.J. The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy. Int. J. Oncol., 2006, 29, 261-268.
207. Ravera, M.; Gabano, E.; Baracco, S.; Sardi, M.; Osella, D. Electrochemical studies of a series of antimetastatic mono- and di- ruthenium complexes [Na][trans-RuIIICl4(DMSO)(L)] and [Na]2[{trans-RuIIICl4(DMSO)}2(l-L)] (L = N-donor heterocyclic bridging ligand). Inorg. Chim. Acta, 2008, 361, 2879-2886.
208. Alessio, E.; Mestroni, G.; Nardin, G.; Attia, W.M.; Calligaris, M.; Sava, G.; Zorzet, S. Cis- and trans-dihalotetrakis(dimethyl sulfoxide)ruthenium(II) complexes (RuX2(DMSO)4; X=Cl, Br): synthesis, structure and antitumor activity. Inorg. Chem., 1988, 27, 4099-4106.
209. Alessio, E.; Mestroni, G.; Bergamo, A.; Sava, G. Ruthenium anticancer drugs. In Metal Ions in Biolgical Systems, Sigel, H.; Sigel, A., Eds., Marcel Dekker: New York, 2004; Vol. 42, pp. 323-351.
210. Groessl, M.; Terenghi, M.; Casini, A.; Elviri, L.; Lobinski, R.; Dyson, P.J. Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MS. J. Anal. At. Spectrom., 2010, 25, 305-313.
211. Frasca, D.R.; Gehrig, L.E.; Clarke, M.J. Cellular effects of transferrin coordinated to [Cl(NH3)(5)Ru]Cl2 and cis- [Cl2(NH3)(4)Ru]Cl. J. Inorg. Biochem., 2001, 83, 139-149.
212. Pongratz, M.; Schluga, P.; Jakupec, M.A.; Arion, V.B.; Hartinger, C.G.; Allmaier, G.; Keppler, B.K. Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy. J. Anal. At. Spectrom., 2004, 19, 46-51.
213. Polec-Pawlak, K.; Abramski, J.K.; Ferenc, J.; Foteeva, L.S.; Timerbaev, A.R.; Keppler, B.K.; Jarosz, M. Application of capillary electrophoresis-inductively coupled plasma mass spectrometry to comparative studying of the reactivity of antitumor ruthenium(III) complexes differing in the nature of counter-ion toward human serum proteins. J. Chromatogr. A, 2008, 1192, 323-326.
214. Messori, L.; Kratz, F.; Alessio, E. The Interaction of the Antitumor Complexes Na[trans-RuCl4(DMSO)(Im)] and Na[trans-RuCl4(DMSO)(Ind)] with Apotransferrin: a Spectroscopic Study. Met. Based Drugs, 1996, 1-9.
215. Mendonza-Ferri, M.G.; Hartinger, C.G.; Mendonza, M.A.; Groessl, M.; Egger, A.; Eichinger, R.; Mangrum, J.B.; Farrell, N.; Maruszak, M.; Bednarski, P.J.; Klein, F.; Jakupec, M.A.; Nazarov, A.A.; Severin, K.; Keppler, B.K. Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity. J. Med. Chem., 2009, 52, 916-925.
216. Piccioli, F.; Sabatini, S.; Messori, L.; Orioli, P.; Hartinger, C.G.; Keppler, B.K. A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans- [RuCl4(Ind)(2)] and serum proteins. J. Inorg. Biochem., 2004, 98, 1135-1142.
217. Timerbaev, A.R.; Foteeva, L.S.; Rudnev, A.V.; Abramski, J.K.; Polec-Pawlak, K.; Hartinger, C.G.; Jarosz, M.; Keppler, B.K. Probing the stability of serum protein-ruthenium (III) drug adducts in the presence of extracellular reductants using CE. Electrophoresis, 2007, 28, 2235-2240.
218. Frasca, D.R.; Ciampa, J.; Emerson, J.; Umans, R.S.; Clarke, M.J. Effects of hypoxia and transferrin on toxicity and DNA binding of ruthenium antitumor agents in HeLa cells. Met. Based Drugs, 1996, 3, 197-209.
219. Haraguchi, H. Metallomics as integrated biometal science. J. Anal. At. Spectrom., 2004, 19, 5-14.
220. Wang, F.Y.; Chen, H.M.; Parkinson, J.A.; Murdoch, P.D.; Sadler, P.J. Reactions of a ruthenium(II) arene antitumor complex with cysteine and methionine. Inorg. Chem., 2002, 41, 4509-4523.
221. Montero, E.I.; Benedetti, B.T.; Mangrum, J.B.; Oehlsen, M.J.; Qu, Y.; Farrell, N.P. Pre-association of polynuclear platinum anticancer agents on a protein, human serum albumin. Implications for drug design. Dalton Trans., 2007, 4938-4942.
222. Reedijk, J. Metal-Ligand Exchange Kinetics in Platinum and Ruthenium Complexes - significance for effectiveness as anticancer drugs. Platinum Met. Rev., 2008, 52, 2-11.
223. Casini, A.; Mastrobuoni, G.; Ang, W.H.; Gabbiani, C.; Pieraccini, G.; Moneti, G.; Dyson, P.J.; Messori, L. ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes. ChemMedChem, 2007, 2, 631-635.
224. Casini, A.; Gabbiani, C.; Michelucci, E.; Pieraccini, G.; Moneti, G.; Dyson, P.J.; Messori, L. Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound. J. Biol. Inorg. Chem., 2009, 14, 761-770.